Pembrolizumab,Lenvatinib,Sunitinib,Everolimus
Merck,Pfizer,eisai
['sunitinib', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)']
 4-yr f/u of phiii clear len+pembro in #1l adv ccrcc adjusted os benefit over sunitinib maintained w/71.3% orr (cr 18.3%) vs 36.7% (cr 5%), depth of response was prognostic of os. dor median 26.7 w/combo vs 14.7 mos w/sunitinib #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope